Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group

Authors: Cortese, Samuele ;

Coghill, David;

Santosh, Paramala;

Hollis, Chris;

Simonoff, Emily

Source: The Lancet Child & Adolescent Health

Full text

: https://doi.org/10.1016/S2352-4642(20)30144-9

Abstract

This addendum to our previous comment provides additional guidance from the European ADHD Guidelines Group (EAGG) on starting attention-deficit hyperactivity disorder (ADHD) medications (specifically psychostimulants and atomoxetine), during the coronavirus disease 2019 (COVID-19) pandemic, for patients who did not have a baseline, face-toface cardiovascular assessment before the crisis began.

Rights

This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Cortese, S., Coghill, D., Santosh, P., Hollis, C. & Simonoff, E. 2020, 'Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group', The Lancet Child & Adolescent Health, 4(6), pp. E15-E15. https://doi.org/10.1016/S2352-4642(20)30144-9

Downloadable citations

HTML BIB RIS

Identifiers

DOI: https://doi.org/10.1016/S2352-4642(20)30144-9

Repository URI: https://discovery.dundee.ac.uk/en/publications/42dc3caa-3472-409c-bb40-ffa413cf77d9